Alimera Sciences, Inc. (ALIM)
USD 5.54
(-0.18%)
USD 5.54
(-0.18%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 153.52 Million USD | 260.37% |
| 2022 | 42.6 Million USD | -27.2% |
| 2021 | 58.52 Million USD | 15.07% |
| 2020 | 50.85 Million USD | 1.09% |
| 2019 | 50.3 Million USD | -7.02% |
| 2018 | 54.1 Million USD | -9.71% |
| 2017 | 59.92 Million USD | -14.67% |
| 2016 | 70.22 Million USD | -0.36% |
| 2015 | 70.48 Million USD | -35.58% |
| 2014 | 109.41 Million USD | 457.66% |
| 2013 | 19.62 Million USD | -62.64% |
| 2012 | 52.52 Million USD | 51.37% |
| 2011 | 34.69 Million USD | -38.49% |
| 2010 | 56.41 Million USD | 240.64% |
| 2009 | 16.56 Million USD | -18.27% |
| 2008 | 20.26 Million USD | -17.35% |
| 2007 | 24.51 Million USD | -21.54% |
| 2006 | 31.25 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 150.37 Million USD | -1.38% |
| 2024 Q1 | 152.48 Million USD | -0.68% |
| 2023 FY | 153.52 Million USD | 260.37% |
| 2023 Q3 | 154.19 Million USD | -0.47% |
| 2023 Q2 | 154.92 Million USD | 221.16% |
| 2023 Q4 | 153.52 Million USD | -0.43% |
| 2023 Q1 | 48.23 Million USD | 13.23% |
| 2022 Q2 | 47.57 Million USD | -4.72% |
| 2022 Q4 | 42.6 Million USD | -1.9% |
| 2022 Q1 | 49.93 Million USD | -14.68% |
| 2022 FY | 42.6 Million USD | -27.2% |
| 2022 Q3 | 43.42 Million USD | -8.71% |
| 2021 Q4 | 58.52 Million USD | -2.57% |
| 2021 FY | 58.52 Million USD | 15.07% |
| 2021 Q1 | 45.58 Million USD | -10.36% |
| 2021 Q2 | 62.1 Million USD | 36.23% |
| 2021 Q3 | 60.06 Million USD | -3.28% |
| 2020 Q3 | 49.08 Million USD | -0.03% |
| 2020 Q2 | 49.09 Million USD | 0.2% |
| 2020 Q1 | 48.99 Million USD | -2.61% |
| 2020 Q4 | 50.85 Million USD | 3.62% |
| 2020 FY | 50.85 Million USD | 1.09% |
| 2019 Q4 | 50.3 Million USD | 7.66% |
| 2019 Q2 | 50.24 Million USD | -3.95% |
| 2019 Q3 | 46.72 Million USD | -6.99% |
| 2019 FY | 50.3 Million USD | -7.02% |
| 2019 Q1 | 52.31 Million USD | -3.32% |
| 2018 Q3 | 51.2 Million USD | -6.63% |
| 2018 Q1 | 56.11 Million USD | -6.35% |
| 2018 FY | 54.1 Million USD | -9.71% |
| 2018 Q4 | 54.1 Million USD | 5.68% |
| 2018 Q2 | 54.83 Million USD | -2.28% |
| 2017 Q3 | 64.75 Million USD | -1.69% |
| 2017 Q2 | 65.87 Million USD | 5.25% |
| 2017 Q1 | 62.59 Million USD | -10.88% |
| 2017 FY | 59.92 Million USD | -14.67% |
| 2017 Q4 | 59.92 Million USD | -7.46% |
| 2016 Q2 | 58.76 Million USD | -5.22% |
| 2016 FY | 70.22 Million USD | -0.36% |
| 2016 Q3 | 74.98 Million USD | 27.59% |
| 2016 Q4 | 70.22 Million USD | -6.34% |
| 2016 Q1 | 62 Million USD | -12.04% |
| 2015 Q2 | 87.32 Million USD | -9.82% |
| 2015 FY | 70.48 Million USD | -35.58% |
| 2015 Q4 | 70.48 Million USD | -10.79% |
| 2015 Q3 | 79.01 Million USD | -9.52% |
| 2015 Q1 | 96.83 Million USD | -11.5% |
| 2014 Q2 | 48.65 Million USD | 2.62% |
| 2014 Q1 | 47.41 Million USD | 141.68% |
| 2014 FY | 109.41 Million USD | 457.66% |
| 2014 Q4 | 109.41 Million USD | 17.28% |
| 2014 Q3 | 93.29 Million USD | 91.73% |
| 2013 Q1 | 43.19 Million USD | -17.76% |
| 2013 Q4 | 19.62 Million USD | -35.75% |
| 2013 Q2 | 37.85 Million USD | -12.36% |
| 2013 FY | 19.62 Million USD | -62.64% |
| 2013 Q3 | 30.53 Million USD | -19.33% |
| 2012 Q2 | 23.73 Million USD | -17.33% |
| 2012 Q4 | 52.52 Million USD | 164.91% |
| 2012 Q1 | 28.71 Million USD | -17.26% |
| 2012 Q3 | 19.82 Million USD | -16.47% |
| 2012 FY | 52.52 Million USD | 51.37% |
| 2011 Q3 | 40.29 Million USD | -12.16% |
| 2011 FY | 34.69 Million USD | -38.49% |
| 2011 Q1 | 51.23 Million USD | -9.18% |
| 2011 Q4 | 34.69 Million USD | -13.89% |
| 2011 Q2 | 45.87 Million USD | -10.46% |
| 2010 Q4 | 56.41 Million USD | 1.15% |
| 2010 Q2 | 61.52 Million USD | 278.61% |
| 2010 Q3 | 55.77 Million USD | -9.36% |
| 2010 Q1 | 16.25 Million USD | -1.87% |
| 2010 FY | 56.41 Million USD | 240.64% |
| 2009 Q3 | 10.88 Million USD | 0.0% |
| 2009 FY | 16.56 Million USD | -18.27% |
| 2009 Q4 | 16.56 Million USD | 52.09% |
| 2008 Q4 | 20.26 Million USD | 0.0% |
| 2008 FY | 20.26 Million USD | -17.35% |
| 2008 Q2 | 34.07 Million USD | -3.72% |
| 2008 Q1 | 35.39 Million USD | 0.0% |
| 2007 FY | 24.51 Million USD | -21.54% |
| 2006 FY | 31.25 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Journey Medical Corporation | 76.84 Million USD | -99.774% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 83.025% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -167.38% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 90.249% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -461.393% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -461.393% |
| SCYNEXIS, Inc. | 128.41 Million USD | -19.556% |
| Safety Shot Inc | 12.7 Million USD | -1107.977% |
| Alpha Teknova, Inc. | 128.58 Million USD | -19.393% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 86.572% |
| Bright Green Corporation | 17.4 Million USD | -782.167% |
| Dynavax Technologies Corporation | 997.09 Million USD | 84.603% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 25.4% |
| Cosmos Health Inc. | 66.29 Million USD | -131.575% |
| PainReform Ltd. | 9.93 Million USD | -1446.062% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -563.829% |
| Embecta Corp. | 1.21 Billion USD | 87.358% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 78.92% |
| Procaps Group, S.A. | 460.18 Million USD | 66.639% |
| Theratechnologies Inc. | 77.76 Million USD | -97.41% |
| Harrow Health, Inc. | 311.75 Million USD | 50.755% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -930.847% |
| Biofrontera Inc. | 27.93 Million USD | -449.635% |
| DURECT Corporation | 45.18 Million USD | -239.738% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 89.104% |
| Cronos Group Inc. | 1.13 Billion USD | 86.465% |
| OptiNose, Inc. | 107.72 Million USD | -42.509% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 67.41% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -174.4% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -566.13% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 66.627% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -1188.15% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -87.737% |
| Radius Health, Inc. | 1.71 Billion USD | 91.053% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -188.108% |
| ProPhase Labs, Inc. | 91.92 Million USD | -67.006% |
| Phibro Animal Health Corporation | 982.18 Million USD | 84.369% |
| Procaps Group S.A. | 460.18 Million USD | 66.639% |
| Alvotech | 950.09 Million USD | 83.841% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -254.485% |
| Viatris Inc. | 47.68 Billion USD | 99.678% |
| Rockwell Medical, Inc. | 52.17 Million USD | -194.259% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -30.0% |
| SIGA Technologies, Inc. | 254.83 Million USD | 39.756% |
| Tilray Brands, Inc. | 4.33 Billion USD | 96.459% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 43.908% |
| Shineco, Inc. | 84.17 Million USD | -82.377% |
| PetIQ, Inc. | 868.22 Million USD | 82.318% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -1719.39% |
| Incannex Healthcare Limited | 17.04 Million USD | -800.592% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 95.278% |
| Silver Spike Investment Corp. | 88.57 Million USD | -73.324% |
| Assertio Holdings, Inc. | 286.41 Million USD | 46.399% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -2479.483% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -354.27% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -391.387% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -1058.887% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 41.207% |
| Hempacco Co., Inc. | 18.04 Million USD | -750.875% |
| Talphera, Inc. | 20.39 Million USD | -652.753% |
| Alvotech | 950.09 Million USD | 83.841% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 62.201% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 90.702% |
| Currenc Group, Inc. | 141.49 Million USD | -8.505% |
| Kamada Ltd. | 351.96 Million USD | 56.381% |
| Indivior PLC | 1.95 Billion USD | 92.132% |
| Evoke Pharma, Inc. | 7.06 Million USD | -2071.932% |
| Flora Growth Corp. | 23.62 Million USD | -549.81% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -1058.887% |
| Evolus, Inc. | 188.99 Million USD | 18.77% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 88.004% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 89.852% |
| Akanda Corp. | 8.83 Million USD | -1636.698% |